-
1.发明授权公开(公告)号：US10966986B2
公开(公告)日：2021-04-06
申请号：US16075077
申请日：2017-02-03
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC.
发明人： Timothy A. Lewis , Alex Burgin , Monica Schenone , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Luc De Waal , Antje Margret Wengner , Knut Eis , Philip Lienau , Ulrike Sack , Martin Lange
IPC分类号： A61K31/5377 , A61K31/50 , C07D413/10 , A61P35/00
摘要： The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
-
2.发明授权公开(公告)号：US12053476B2
公开(公告)日：2024-08-06
申请号：US17161612
申请日：2021-01-28
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC.
发明人： Timothy A. Lewis , Alex Burgin , Monica Schenone , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Luc De Waal , Antje Margret Wengner , Knut Eis , Philip Lienau , Ulrike Sack , Martin Lange
IPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
CPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
摘要： The present invention features improved compounds, especially
methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).-
公开(公告)号：US11207320B2
公开(公告)日：2021-12-28
申请号：US15752130
申请日：2016-08-12
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Bayer Pharma Aktiengesellschaft
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , G01N33/574 , A61P35/00 , A61K9/00 , A61K31/519
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
公开(公告)号：US20220071995A1
公开(公告)日：2022-03-10
申请号：US17530402
申请日：2021-11-18
申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , Bayer Pharma Aktiengesellschaft
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , G01N33/574 , A61P35/00 , A61K9/00 , A61K31/519
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
公开(公告)号：US20180235961A1
公开(公告)日：2018-08-23
申请号：US15752130
申请日：2016-08-12
发明人： Luc De Waal , Matthew Meyerson , Heidi Greulich , Monica Schenone , Alex Burgin , Xiaoyun Wu , Ulrike Sack
IPC分类号： A61K31/50 , A61K9/00 , A61P35/00 , G01N33/574
CPC分类号： A61K31/50 , A61K9/0019 , A61K9/0053 , A61K31/519 , A61K2300/00 , A61P35/00 , G01N33/57488 , G01N2333/916 , G01N2800/52
摘要： The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
-
-
-
-
搜索结果
5 条记录 (耗时 0.027 秒)
